•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
On 23 April, Lian SGP Holding Pte. Ltd purchased 104,545,781 IMP shares from 109 investors at the price of 57,400 dong per share. Imexpharm Joint Stock Company (IMP) announced the results of its public tender offer for IMP shares by Lian SGP Holding Pte. Ltd, with an expected tendered share amount of 120,059,970 shares, representing 77.94% of Imexpharm's charter capital and 77.96% of voting shares, at a bid price of 57,400 dong per share. The registration period for selling was from 13 March to 23 April 2026. The public tender agent was SSI - Hanoi branch. At the end of this period, Lian SGP Holding Pte. Ltd had purchased 104,545,781 IMP shares from 109 investors at 57,400 dong per share. After the tender, Lian SGP and its related parties owned 104,545,781 shares, equal to 67.87% of IMP's charter capital. On 28 April, the stock closed down 1.76% to 47,500 dong per share. Lian SGP Holding Pte. Ltd. is a Singapore-registered company 100% owned by Livzon Pharmaceutical Group Inc. Its registered capital is USD 300 million (about VND 7,825.8 billion). The company is headquartered in Singapore. Its main activities involve investing, holding, and managing equity interests in other companies, as well as supervising the operations of subsidiaries and affiliates. Imexpharm has successfully held its 2026 annual general meeting. Net profit after tax was over 349 billion dong. The company will pay the 2025 cash dividend at a rate of 6% to shareholders no later than 30 days, and not more than three months after the AGM. For 2026, IMP targets total revenue of 3,200 billion dong, up 9.8% from 2025 (2,914.3 billion dong); pretax profit of 502 billion dong, up 12.5% from 2025 (446.2 billion); EBITDA of 637 billion dong, up 12.3% from 2025 (567.2 billion). The expected dividend is 5-8% of charter capital. The outlook reflects the overall impact on the Vietnamese pharmaceutical sector, where market demand is growing slowly and competition is intense. Consequently, Q1 2026 net revenue declined by 47.852 billion dong, an 8.1% year-on-year decrease. Additionally, the company restructured its product portfolio and improved cost control in selling and general administration, lifting Q1 2026 net profit after tax by 7.558 billion dong, a roughly 10.1% increase year-on-year.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
